Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 5, 2014, Pages 1436-1439

  Nozza, Silvia ^a   Bigoloni, Alba ^a   Calcagno, Andrea ^b   Galli, Laura ^a   Pignataro, Angela Rosa ^a   D'Avolio, Antonio ^b   Carbone, Alessia ^a   Ripa, Marco ^a   Bonora, Stefano ^b   Lazzarin, Adriano ^a   Castagna, Antonella ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Multidrug resistance; Raltegravir andmaraviroc dosing; Simplification

Indexed keywords

DARUNAVIR PLUS RITONAVIR; ETRAVIRINE; MARAVIROC; RALTEGRAVIR; VIRUS RNA; 2 PYRROLIDONE DERIVATIVE; CYCLOHEXANE DERIVATIVE; TRIAZOLE DERIVATIVE;

CD4 LYMPHOCYTE COUNT; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FOLLOW UP; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INTENTION TO TREAT ANALYSIS; LETTER; MEDICATION COMPLIANCE; REBOUND; TREATMENT DURATION; VIRAL TROPISM; VIRUS LOAD; VIRUS RESISTANCE; ANTIVIRAL RESISTANCE; DRUG EFFECTS; FEMALE; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; MISSENSE MUTATION; TREATMENT FAILURE;

CYCLOHEXANES; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; PYRROLIDINONES; TREATMENT FAILURE; TRIAZOLES; VIRAL LOAD;

EID: 84898419784     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt530     Document Type: Letter

References (10)

1. Negredo E, Mirò O, Rodriguez-Santiago B et al. Improvement of mitochondrial toxicity in patients receiving a nucleoside reversetranscriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA). Clin Infect Dis 2009; 49: 892-900.
2. Burgos J, CrespoM, Falcó Vet al. Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients. J Antimicrob Chemother 2012; 67: 2479-86.
3. Bonjoch A, Pou C, Pé rez-Á lvarez N et al. Switching the third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot, prospective, randomized clinical trial. J Antimicrob Chemother 2013; 68: 1382-7.
4. Eron JJ, Young B, Cooper DA et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010; 375: 396-407.
5. D'Avolio A, Simiele M, Baietto L et al. Avalidated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients. Ther Drug Monit 2010; 32: 86-92.
6. D'Avolio A, Baietto L, Siccardi M et al. HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients. Ther Drug Monit 2008; 30: 662-9.
7. Nozza S, Galli L, Bigoloni A et al. Durability and safety of a novel salvage therapy in R5-tropic HIV-infected patients: maraviroc, raltegravir, etravirine. J Acquir Immune Defic Syndr 2011; 56: e113-5.
8. Katlama C, Assoumou L, Valantin MA et al. Maraviroc plus raltegravir dual therapy in aviremic HIV infected patients with lipodystrophy: results from the ROCnRAL ANRS 157 study. In: Abstracts of the Twentieth Conference on Retroviruses and Opportunistic Infections, Atlanta, GA, USA, 2013. Abstract P566. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
9. Calcagno A, Nozza S, Bonora S, Castagna et al. Pharmacokinetics of the raltegravir/maraviroc/etravirine combination. J Antimicrob Chemother 2011; 66: 1932-4.
10. Le M, Soulié C, Chablais L et al. Plasma concentrations of dualmaraviroc/ raltegravir combination in patients with suppressed viremia: results from ROCnRAL ANRS157 sub-study. In: Abstracts of the Fourteenth PK Workshop, Amsterdam, The Netherlands, 2013. Abstract P32.